By: IPP Bureau
Last updated : May 19, 2026 7:09 am
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
NunaBio, a United Kingdom-based next-generation DNA manufacturing company, has raised £6.5 million in funding to expand its proprietary DNA manufacturing platform and accelerate its growth as an infrastructure-focused business serving synthetic biology, therapeutics and research markets.
The investment will support the continued development of NunaBio’s integrated DNA platform, which combines multiple enzymatic technologies with proprietary hardware to deliver DNA manufacturing at higher speed, scale and sequence complexity than conventional production methods.
Joe Hedley, CEO and Co-Founder, NunaBio, said: “This investment marks an important step in scaling a fundamentally new approach to DNA manufacturing. Our focus is on enabling DNA that others cannot produce and translating that capability into a robust, industrial platform.”
“Our long-term vision is a globally deployable network of DNA micro-foundries - compact, automated production units applying semiconductor-style manufacturing principles to biology. By standardising and modularising production, we can deliver scalable, high-performance DNA manufacturing without the constraints of traditional approaches,” he added.
The funding round was led by Northstar Ventures through investments from the UK’s North East Spinout Inspire Fund and the Northstar EIS Growth Fund, both focused on supporting high-impact technology companies emerging from North East England.
Alex Buchan, Investment Director, Northstar Ventures, said, “NunaBio is developing a highly differentiated approach to DNA manufacturing with significant potential across a range of high-growth applications. We identified NunaBio’s potential to transform industry economics from early on. We are pleased to support the company as it scales its technology and commercial reach.”